Skip to main content

Table 6 Comparison of treatment outcome, based on an immediate NPV ratio of 80%, between groups 1 and 2

From: Volumetric magnetic resonance-guided high-intensity focused ultrasound ablation of uterine fibroids through abdominal scars: the impact of a scar patch on therapeutic efficacy and adverse effects

Treatment outcome

Group 1

Group 2

 

≥80%

(n = 12)

<80%

(n = 5)

P value

≥80%

(n = 40)

<80%

(n = 6)

P value

Fibroid volumea

 Baseline

  

0.208

  

0.765

  Mean ± SD

214.9 ± 200.0

94.2 ± 33.7

 

171.3 ± 137.0

152.7 ± 173.6

 

  Range

37.0–794.0

51.0–143.0

 

6.0–637.0

12.0–478.0

 

 6 months

  

0.925

  

0.057

  Mean ± SD

88.8 ± 79.8

85.2 ± 36.2

 

83.1 ± 71.0

167.5 ± 215.1

 

  Range

11.0–295.0

41.0–140.0

 

4.0–400.0

10.0–578.0

 

 Reduction ratio (6 months)

  

0.001*

  

0.001*

  Mean ± SD

0.6 ± 0.15

0.11 ± 0.11

 

0.49 ± 0.13

0.03 ± 0.16

 

  Range

0.25–0.8

−0.03–0.2

 

0.22–0.84

−0.21–0.18

 

Symptom severity scoreb

 Baseline

  

0.916

  

0.155

  Mean ± SD

54.7 ± 14.4

55.6 ± 21.0

 

51.6 ± 16.1

62.0 ± 17.7

 

  Range

31.2–75.0

31.2–87.5

 

21.9–84.4

43.7–93.7

 

 6 months

  

0.001*

  

0.001*

  Mean ± SD

4.2 ± 5.0

46.2 ± 16.9

 

6.2 ± 7.5

47.9 ± 31.8

 

  Range

0.0–15.6

18.7–62.5

 

0.0–37.5

6.2–100.0

 

 Improvement ratio (6 months)

  

0.001*

  

0.001*

  Mean ± SD

0.93 ± 0.8

0.15 ± 0.27

 

0.88 ± 0.14

0.25 ± 0.36

 

  Range

0.75–1.0

−0.2–0.43

 

0.5–1.0

−0.07–0.89

 
  1. SD standard deviation
  2. aLargest treated fibroid only
  3. bTransformed symptom severe score (SSS) can range from 0 to 100
  4. *Statistically significant